

ResMed launches AirSense 11 to advance digital health in sleep apnea for Indians

06 January 2025 | News

2024 ResMed Global Sleep Survey reports that 46% of respondents have a diagnosed history of sleep apnea



ResMed, the world's leading health technology company focused on sleep, breathing, and care delivered in the home, has launched AirSense 11 in India, the company's next-generation Continuous Positive Airway Pressure (CPAP) device designed to make it easier for individuals with Obstructive Sleep Apnea (OSA) to start and stay on therapy.

As the most common sleep-related breathing disorder, OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common sign being snoring.

To address the rising cases of sleep apnea in India, ResMed has introduced the AirSense 11, which includes new features like Personal Therapy Assistant and Care Check-In designed to provide tailored guidance to PAP users, helping ease them into therapy and comfortable nightly use. Other features include the availability of remote software updates so users can enjoy the latest version of these tools every night.

The AirSense 11 includes access to myAir (ResMed's patient engagement app) and AirView (ResMed's remote monitoring platform for clinicians), which help bring overall patient adherence as high as 87%. The myAir app tracks the time patients spend using CPAP therapy, the number of sleep apnea events per hour, mask leaks, and the number of times a mask was removed, providing nightly data on breathing, coaching tips, and support directly to their phone.

AirView provides a secure, cloud-based patient management system for online patient monitoring that enables healthcare professionals to access patient data quickly, share clinical insights with other health professionals, improve care and reduce costs related to patient follow-up.